China Biologic Products Holdings

Taibang Biologic Group is a Chinese biopharmaceutical company that provides a comprehensive range of plasma-derived products. The company's core business includes the development, manufacture, and sale of plasma-derived products and other biopharmaceutical products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger Sub"), a wholly owned subsidiary of CBPO Holdings Limited ("Parent"), pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement") among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

China Biologic Announces Completion of Going Private Transaction

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019.

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript

BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2020 financial...

China Biologic Products to Report Third Quarter 2020 Financial Results

Galapagos

Heron Therapeutics

Illumina

Ionis Pharma

REGENXBIO

Ligand Pharmaceuticals

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript

Avon Products

Carlyle Group

Kinross Gold

ManTech

Vipshop Hlds

Aqua America

These stocks slot into any portfolio and will pack a special punch.

7 Ideal Mid-Cap Stocks for a Diverse Portfolio

ACADIA Pharma

Arrowhead Pharmaceuticals

Natera

Spark Therapeutics

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript

As of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share.

Go-Private Offer For China Biologic Products: It Is Undervalued

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript

BBVA Banco Frances SA Sponsored ADR

Discover

Magna International

AMERCO

According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.

5 Undervalued Stocks Growing Book Value

China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript

China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline

Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for

News for China Biologic Products Holdings Stock (CBPO)